Related Experiment Video
Updated: May 5, 2026
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
1.0K
Prognostic factors associated with solitary plasmacytoma
Shan-Qi Guo1, Le Zhang, Ya-Fei Wang
1Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, People's Republic of China.
Oncotargets and Therapy
|November 22, 2013
Summary
Solitary plasmacytoma (SP) is a rare plasma cell tumor. This study analyzed 66 SP patients, identifying clinical features and prognostic factors for solitary bone plasmacytoma and extramedullary plasmacytoma.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Solitary plasmacytoma (SP) is a rare plasma cell neoplasm.
- It represents a distinct entity from multiple myeloma.
- Understanding SP's characteristics is crucial for patient management.
Purpose of the Study:
- To investigate the clinical features of SP.
- To evaluate treatment strategies for SP.
- To identify prognostic factors in SP patients.
Main Methods:
- Retrospective analysis of 66 SP patients.
- Data collected over 12 years at a single institution.
- Comparison of solitary bone plasmacytoma (SBP) and extramedullary plasmacytoma (EMP) groups.
Main Results:
- SP comprises 10.25% of plasma cell dyscrasias.
- SBP commonly affects the vertebral column; EMP occurs in the upper respiratory tract.
- Tumor size, M protein, Bence Jones protein, and progression to multiple myeloma differed significantly between SBP and EMP.
- Larger SBP tumors (≥5 cm) correlated with poorer outcomes.
- Radiotherapy and low serum β2 microglobulin (<3.5 mg/L) were favorable for EMP prognosis.
Conclusions:
- SP presents as either SBP or EMP with distinct clinical behaviors.
- Prognostic factors vary between SBP and EMP.
- Tailored treatment and monitoring are essential for optimizing outcomes in SP.
